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Subcellular localization influences the nature of Ras/extracellular signal-regulated kinase (ERK) signals by
unknown mechanisms. Herein, we demonstrate that the microenvironment from which Ras signals emanate
determines which substrates will be preferentially phosphorylated by the activated ERK1/2. We show that the
phosphorylation of epidermal growth factor receptor (EGFr) and cytosolic phospholipase A2 (cPLA2) is most
prominent when ERK1/2 are activated from lipid rafts, whereas RSK1 is mainly activated by Ras signals from the
disordered membrane. We present evidence indicating that the underlying mechanism of this substrate selectivity
is governed by the participation of different scaffold proteins that distinctively couple ERK1/2, activated at defined
microlocalizations, to specific substrates. As such, we show that for cPLA2 activation, ERK1/2 activated at lipid rafts
interact with KSR1, whereas ERK1/2 activated at the endoplasmic reticulum utilize Sef-1. To phosphorylate the
EGFr, ERK1/2 activated at lipid rafts require the participation of IQGAP1. Furthermore, we demonstrate that
scaffold usage markedly influences the biological outcome of Ras site-specific signals. These results disclose an
unprecedented spatial regulation of ERK1/2 substrate specificity, dictated by the microlocalization from which Ras
signals originate and by the selection of specific scaffold proteins.
Ras GTPases operate as key molecular switches that convey
extracellular signals from surface receptors to the interior of
the cell, thereby regulating essential processes, including pro-
liferation, differentiation, and survival (10). It has been long
known that Ras proteins must be attached to the inner leaflet
of the plasma membrane (PM) to be functional, but only re-
cently has it been established that Ras isoforms are distinc-
tively segregated in different PM microdomains: H-Ras can be
found in the bulk membrane and in lipid rafts, both caveolar
and noncaveolar. K-Ras is exclusively located in the bulk mem-
brane (27, 28), while N-Ras is mainly detected in noncaveolar
lipid rafts (20). Moreover, Ras proteins are present and func-
tional in endomembranes, such as endosomes, the endoplas-
mic reticulum (ER), and the Golgi complex (9, 26, 32). How-
ever, how these distinct microenvironments affect the signals
generated by Ras is just beginning to be unfolded. In this
respect, recent findings support the notion that the Ras signals
emanating from these different sublocalizations are quantita-
tively and qualitatively different, in the effector routes that they
engage in and in the resulting transcriptomal and biological
outcomes (1, 9, 15, 21).
The pathway leading to the activation of extracellular signal-
regulated kinase 1 and 2 (ERK1/2) mitogen-activated protein
kinases is a key component of Ras signals (29). To date, evi-
dence is mounting indicating that the cellular microenviron-
ment can play an essential role in the regulation of ERK1/2
functions. ERK1/2 can be regulated by processes strictly de-
pendent on subcellular localization (33), and ERK1/2 them-
selves regulate some biochemical processes in a compartment-
dependent fashion (14). Furthermore, the balance among
different compartment-specific components of ERK1/2 signals
seems determinant for the biological outcomes resulting from
ERK1/2 activation (3, 30). ERK1/2 phosphorylate a great
variety of substrates distributed in different subcellular local-
izations and microenvironments (40). However, whether, de-
pending on the activating stimuli, ERK1/2 display variable
selectivity toward these different pools of substrates and the
extent to which the subcellular atmosphere can regulate
ERK1/2 interactions with their cognate targets are largely
unanswered issues.
ERK1/2 signals are modulated by different types of regula-
tory proteins. Scaffold proteins serve such a purpose by con-
necting the different components of the cascade into an enzy-
matic macrostructure by which the amplitude and duration of
ERK1/2 signals are fine-tuned, while providing signal fidelity
by isolating the signaling complex from undesired, molecular
interferences (12, 17, 23). Furthermore, scaffolds can also serve
a role in the spatial control of ERK1/2 signals by regulating
their activity in a sublocalization-specific fashion. In this re-
spect, KSR1 acts preferentially on ERK1/2 signals emanating
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from PM cholesterol-rich domains (22). MP-1 regulates
ERK1/2 at endosomes (35), Sef regulates ERK1/2 at the Golgi
complex (37), and paxillin regulates ERK1/2 at focal adhesions
(16). But the precise mechanisms whereby scaffolds can
achieve spatial specificity for ERK1/2 signals are largely un-
known.
Herein, we have taken a look at these questions. We dem-
onstrate that the signaling platform from which the activating
Ras signals spring dictates ERK1/2 selectivity toward different
substrates. In this process, we unveil the participation of scaf-
fold proteins that distinctively couple ERK1/2 activated at de-
fined microlocalizations to specific substrates. Our results pro-
vide the first evidence pointing both to the activating signal
microenvironment and to a differential scaffold usage, as reg-
ulators of ERK1/2 substrate specificity.
MATERIALS AND METHODS
Plasmids. The expression vectors encoding the localization-targeted H-RasV12
and the wild type (5, 21) have been previously described. Myc-Sef was a gift from
Z. Chang (38). UO126, SB203580, and epidermal growth factor (EGF) were
from Calbiochem. Lysophosphatidic acid (LPA) and tetradecanoyl phorbol ac-
etate (TPA) were from Sigma.
Cell culture and transfection. HEK293T cells and wild-type, H-Ras/
N-Ras/ (H/N-Ras/) and Ksr/ mouse embryonic fibroblasts (MEFs) were
grown in Dulbecco’s modified Eagle’s medium-10% fetal calf serum, and NIH
3T3 cells were grown in 10% calf serum. Subconfluent cells were transfected by
Lipofectamine. Small interfering RNAs (siRNAs) were from Dharmacon; a pool
of four different siRNAs was used in each particular case. Sequences are avail-
able upon request. siRNAs were transfected by following the manufacturer’s
guidelines.
Immunoblotting and immunoprecipitations. Immunoblotting and immuno-
precipitations were performed exactly as described previously. Immunoprecipi-
tations were performed for lysates normalized by total protein contents (33).
Mouse monoclonal antihemagglutinin (anti-HA), -Myc, and -AU5 were from
Covance. The mouse monoclonal antibodies anti-ERK1/2 and -phospho-ERK;
the rabbit polyclonals anti-KSR1, -RSK1, -caveolin, and -phospho-RSK1; and
the goat polyclonal anti-cytosolic phospholipase A2 (anti-cPLA2) were from
Santa Cruz. The mouse monoclonal antibodies anti-Elk1 and -phospho-Elk1
were from Cell Signaling. The mouse monoclonal antibodies anti-IQGAP1 and
-transferrin receptor were from BD Transduction. The rabbit polyclonal anti-
EGF receptor (anti-EGFr) was a gift from Atanasio Pandiella (Salamanca).
Nucleocytoplasmic fractionations. Nucleocytoplasmic fractionations were per-
formed as described previously (3).
S100/P100 separations. S100/P100 separations were performed as described
previously (4).
Sucrose gradients. Cells were resuspended in 25 mM Tris (pH 7.4), 150 mM
NaCl, 5 mM EDTA, and 0.25% Triton X-100 with rocking at 4°C for 1 h. The
lysates were set to a sucrose concentration of 41%. Layers of 8.5 ml of 35%
sucrose (in 10 mM Tris [pH 7.4]) and of 2.5 ml of 16% sucrose were sequentially
overlaid and centrifuged in a Beckman SW41 rotor for 18 h at 35,000 rpm. Ten
to 12 1-ml fractions were collected, precipitated in 6.5% trichloroacetic acid,
resuspended in loading buffer, and fractionated on 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis gels.
cPLA2 activation assays. The cPLA2 activation assays were performed as
described previously (33). Briefly, cells were labeled with [3H]arachidonic acid (1
Ci per well in a 24-well plate) for 18 h. The cells were then washed twice with
phosphate-buffered saline (PBS), and new medium (Dulbecco’s modified Eagle’s
medium–1% fatty acid-free bovine serum albumin) was added. Where indicated,
the cells were stimulated with EGF (100 ng/ml) for 30 min. The medium was
removed and centrifuged at 2,000  g, and free, labeled arachidonic acid re-
leased into the medium was measured by liquid scintillation counting.
EGFr phosphorylation assays. 32P metabolic labeling was performed as de-
scribed previously (33). After 18 h of starvation and upon treatment with mito-
gens or inhibitors where appropriate, the cells were lysed and the lysates were
immunoprecipitated with anti-EGFr antibody. The immunoprecipitates were
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and
EGFr phosphorylation was made evident by prolonged exposition of the
dried gel.
Focus formation and senescence assays in MEFs. The focus formation and
senescence assays were performed exactly as described previously (18).
Luciferase assays. Luciferase assays were performed as described previously
(33), using the reporter pGE51-luc and a vector encoding the transactivation
domain of Elk-1 (amino acids 307 to 428) fused to the GAL4 DNA-binding
domain. The luciferase activities were determined using a commercial kit (Pro-
mega, Madison, WI) and normalized by the -galactosidase activity.
Immunofluorescence. Cells were grown on glass slides, washed twice in PBS,
fixed with 3.7% formaldehyde in PBS for 10 min at room temperature, and
permeabilized, when necessary, with 0.5% Triton X-100–PBS for 20 min. The
preparations were sequentially incubated with 0.5% Triton X-100–PBS for 15
min and 0.1 M glycine-PBS for 30 min and blocked with 1% bovine serum
albumin, 0.01% Tween 20 in PBS for 5 min. The preparations were then rinsed
in PBS–0.05% Tween 20, incubated for 1 h with the primary antibody, washed,
and incubated for 45 min with the appropriate secondary antibodies. Coverslips
were mounted in VectaShield and sealed with nail polish. Confocal microscopy
was performed with a Bio-Rad MRC-1024 microscope, using excitation wave-
lengths of 488 nm.
RESULTS
ERK1/2 cytoplasmic substrates are differentially activated
depending on Ras localization. To take an initial glance into
how Ras sublocalization affected ERK1/2 functions, we looked
at the activation of several bona fide ERK1/2 substrates, which
are known to be present in different subcellular compartments.
To this end, we utilized the previously described H-RasV12
constructs selectively tethered to defined microlocalizations by
specific localization signals: the ER (avian infectious bronchitis
virus M1 protein), lipid rafts (LCK myristoylation signal), the
disordered membrane (CD8 transmembrane domain), and
the Golgi complex (KDEL receptor N193D) (21), transiently
expressed in 293T cells. With the exception of the Golgi signal,
which evoked little ERK activation, endogenous ERK1/2 were
activated to similar levels independently of Ras localization
and of Ras expression levels (Fig. 1A). The expression levels of
the different site-specific Ras constructs were determined by
the amount of Ras that can fit into each of the sublocalizations,
rather than on the intrinsic expression capacity of the con-
structs themselves, as extensively discussed before (21). This
pattern of activation was almost identical to that previously
described for NIH 3T3 cells stably expressing these targeted
RasV12 constructs (21).
First, we explored whether the platform in which Ras-acti-
vating signals were generated could determine if the activated
ERK1/2 preferentially selected substrates localized at distinct
sites. We assayed the phosphorylation of the EGFr, an ERK
substrate localized at the PM (24). The 293T cells were trans-
fected with the targeted RasV12 constructs and metabolically
labeled with orthophosphate in order to disclose the phosphor-
ylation of EGFr. It was found that EGFr was intensively phos-
phorylated in cells expressing RasV12 at lipid rafts and, to a
lesser extent, at the disordered membrane. On the other hand,
RasV12 at endomembranes, whether ER or Golgi, was not
capable of inducing a substantial phosphorylation of the EGFr
(Fig. 1B, top panels). To validate that the RasV12 signals
inducing the phosphorylation of EGFr were mediated by
ERK1/2, we used the MEK inhibitor UO126, which was shown
to completely inhibit the phosphorylation of EGFr induced by
Ras, irrespective of its localization (Fig. 1B, bottom panels). In
NIH 3T3 cells expressing ectopic EGFr, LCK-RasV12 could
evoke the phosphorylation of a protein of the same size as the
one detected in 293T cells, whereas in parental NIH 3T3 cells
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that do not express EGFr, this band was not apparent (data not
shown), thereby validating EGFr identity. Since protein kinase
D can phosphorylate EGFr (6), we investigated the possible
participation of this kinase by suppressing its expression using
siRNA interference. It was found that the downregulation of
protein kinase D had no effects on EGFr phosphorylation
induced by RasV12 (data not shown).
We then determined if ERK1/2 cytoplasmic substrates were
also subject to differential regulation depending on the Ras
activation site. To do so, we monitored RSK1, a substrate
phosphorylated by ERK1/2 primarily at the cytoplasm (13).
Both in NIH 3T3 and in 293T cells, RSK1 phosphorylation was
most prominent when induced by Ras signals originated at the
disordered membrane. UO126 completely abrogated RSK1
FIG. 1. Ras sublocalization defines ERK1/2 substrate specificity. (A) Phosphorylation of ERK1/2 resulting from compartmentalized Ras
activation. 293T cells were transfected with H-RasV12 (0.5 g), untargeted (V12) or specifically tethered to the ER (M1), lipid rafts (LCK), the
disordered membrane (CD8), or the Golgi complex (KDELr). Phosphorylated and total ERK1/2 levels were determined in total lysates by
immunoblotting. Anti-HA Western blotting (WB) reveals the expression levels of the Ras constructs. C, control. (B) Phosphorylation of EGFr
resulting from compartmentalized Ras activity. Top panel, EGFr phosphorylation was determined by immunoprecipitation (IP) in 32P-labeled
293T cells transfected with the Ras constructs. Bottom panel, EGFr phosphorylation is ERK dependent. 293T cells transfected with the targeted
Ras constructs and incubated with 2 M U0126 for 2 h () were analyzed for EGFr phosphorylation. (C) Phosphorylation of RSK1 induced by
compartmentalized Ras activation. Total and phosphorylated RSK1 levels were determined in starved NIH 3T3 and 293T cells expressing the Ras
constructs. Right panel, RSK1 phosphorylation is ERK dependent. 293T cells transfected with H-RasV12 and incubated with U0126 for 2 h ()
were analyzed for RSK1 phosphorylation. (D) Regulation of cPLA2 activation by Ras sublocalization.
3H-labeled arachidonic acid release was
measured in NIH 3T3 cells. (E) ERK1/2 substrate specificity is unaffected by targeted Ras expression levels. Cells were transfected with increasing
concentrations (0.5 to 5 g) of LCK- or CD8-RasV12 and RSK1 phosphorylation and cPLA2 activation were examined. (D and E) Shown are the
averages  standard errors of the means of the results from three independent experiments relative to the levels in the control cells. , anti.
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phosphorylation induced by RasV12 (Fig. 1C), demonstrating
that ERK1/2 were the sole mediators in this event. It was
important to know whether other ERK cytoplasmic substrates
responded similarly or if this behavior was unique for RSK1.
As such, we analyzed a second cytoplasmic substrate, cPLA2
(19). Upon examination of radiolabeled arachidonic acid re-
lease in cells expressing the tethered Ras constructs, it was
found that cPLA2 was activated mostly by Ras at lipid rafts
and, to a lesser extent, by signals elicited from the ER (Fig.
1D). These results demonstrated that ERK1/2 activated from
different Ras signaling platforms selectively targeted distinct
cytoplasmic substrates. To ascertain that ERK1/2 substrate
selectivity was not altered by the levels of the targeted Ras
proteins, we analyzed cPLA2 and RSK1 activation in response
to increasing concentrations of LCK- or CD8-RasV12. As
shown in Fig. 1E, even the highest levels of active Ras at the
disordered membrane failed to affect cPLA2 activation. Like-
wise, Ras targeted to lipid rafts could not elicit any significant
RSK1 phosphorylation, irrespective of its expression levels.
Ras localization does not affect ERK1/2 nuclear substrates.
Next, we focused on ERK1/2 nuclear substrates. Noticeably, in
NIH 3T3 cells expressing the Ras constructs, the phosphory-
lation of Elk1 transcription factor, induced by untargeted
RasV12, was remarkably higher than that generated by the
site-specific RasV12 constructs, among which there were no
major differences. Only Ras signals emanating from the Golgi
complex were slightly less effective. Similar results were ob-
served in 293T cells (Fig. 2A). To further substantiate this
observation, we looked at how Ras sublocalization affected
phosphorylated ERK1/2 nuclear influx. To this end, nuclear
and cytoplasmic fractions were purified from 293T cells ex-
pressing the targeted Ras constructs. It was found that Ras
sublocalization was not a factor for determining ERK1/2 nu-
cleocytoplasmic distribution, again except with Golgi Ras sig-
nals, which were less effective for eliciting ERK1/2 nuclear
entry (Fig. 2B).
Since Elk1 is also a substrate for other MAPKs, such as p38
and JNK, we investigated the contribution of each of these
MAPKs to its phosphorylation, in response to compartmental-
ized Ras signals. For this, we utilized a GAL4-Elk1-dependent
luciferase reporter. Emulating the results obtained by assaying
Elk1 phosphorylation, untargeted RasV12 induced the great-
est transactivation of the Elk1 reporter, whereas few differ-
ences were found among the site-specific Ras constructs (Fig.
2C, left panel). The depletion of ERK1/2 levels by siRNA
interference (Fig. 2C, right panel) resulted in pronounced
FIG. 2. Effects of Ras sublocalization on the activation of ERK1/2 nuclear substrates. (A) Phosphorylation of Elk1 by compartmentalized Ras
signals. Total and phosphorylated Elk1 levels were determined by immunoblotting in NIH 3T3 and 293T cells expressing the targeted Ras
constructs. C, control. (B) Effects of compartmentalized Ras signals on ERK1/2 nucleocytoplasmic distribution. Total and phosphorylated ERK1/2
levels were examined in nuclear (N) and cytoplasmic (C) fractions from 293T cells expressing the targeted Ras constructs. Bottom panel, the purity
of the fractions was ascertained by blotting against Rho-GDP dissociation inhibitor (GDI) and Elk1. (C) Elk1 activation dependence on Ras
compartmentalized signals. Left panel, Elk1 transactivation was assayed in NIH 3T3 cells transfected with GAL4-Elk1 and the targeted Ras
constructs plus siRNAs against ERK1 and -2 or JNK1 and -2 (10 ng), as shown in the key. C, control. Shown are the averages  standard errors
of the means of the results from three independent experiments relative to the levels in the control cells. Right panel, diminished expression of
the endogenous mitogen-activated protein kinases resulting from siRNA treatments. V12, untargeted H-RasV12; M1, H-RasV12 specifically
tethered to the ER; LCK, H-RasV12 specifically tethered to lipid rafts; CD8, H-RasV12 specifically tethered to the disordered membrane; KDELr,
H-RasV12 specifically tethered to the Golgi complex.
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drops in Elk1 transactivation in all cases. Noticeably, Elk1
activation elicited by Golgi Ras signals was the least responsive
to ERK1/2 downregulation but was the most affected by
JNK1/2 decline. On the other hand, p38 inhibition by treat-
ment with SB203580 was ineffective in all cases (data not
shown).
It was essential to validate the above findings in a physio-
logically relevant context. For this purpose, we resorted to
fibroblasts obtained from H-Ras/N-Ras knockout mice, in
which lipid rafts are completely devoid of Ras (21), since K-
Ras is exclusively located in disordered membrane (27). We
reasoned that in these cells, the phosphorylation of ERK sub-
strates regulated by Ras signals from lipid rafts, but not of
those regulated from disordered membrane, should be com-
promised. In these MEFs, ERK1/2 activation resulting from
EGF stimulation was significantly reduced compared to that in
wild-type MEFs (Fig. 3A). When we evaluated the activation
of cPLA2 in H/N-Ras
/ MEFs, the response to EGF was
reduced by nearly 70% in comparison to that of the wild-type
MEFs (Fig. 3B). The same situation occurred when we ana-
lyzed EGFr phosphorylation induced by LPA stimulation (Fig.
3C). Conversely, EGF-induced RSK1 and Elk1 phosphoryla-
tions were similar to those encountered in wild-type MEFs
(Fig. 3D), thereby corroborating our hypothesis. To further
ascertain our case, we restored Ras at the lipid rafts of H/N-
Ras/ MEFs by transfecting them with the LCK–H-Ras wild
type. The renewed presence of Ras in lipid rafts markedly
rescued cPLA2 activation upon EGF stimulation (Fig. 3E),
whereas in cells transfected with H-Ras tethered to the ER, the
rescue of cPLA2 activation was only modest and insignificant in
FIG. 3. cPLA2 but not RSK1 activation is impaired in MEFs devoid of Ras at lipid rafts. (A) ERK1/2 activation in H/N-Ras
/ MEFs. Total
and phosphorylated ERK1/2 levels were analyzed in wild type (wt) and H/N-Ras/ MEFs after starvation () and stimulation with 10 ng/ml EGF
for 5 min (). Figures show ERK1/2 phosphorylation levels relative to those found in unstimulated, wild-type MEFs. (B) cPLA2 activation is
impaired in H/N-Ras/ MEFs. 3H-labeled arachidonic acid release was measured in wild-type and H/N-Ras/ MEFs after stimulation () with
EGF. Shown are the averages standard errors of the means of the results from three experiments relative to the levels in unstimulated cells. ***,
P  0.001, with a 95% confidence interval. (C) EGFr phosphorylation is impaired in H/N-Ras/ MEFs. EGFr phosphorylation was assayed in
wild-type and H/N-Ras/ MEFs after stimulation with LPA (5 M) for 5 min (). (D) Phosphorylation of RSK1 and Elk1 is unaffected in
H/N-Ras/ MEFs. Total and phosphorylated RSK1/Elk1 levels were determined by immunoblotting in wild-type and H/N-Ras/ MEFs after
stimulation with EGF. (E) The presence of Ras at lipid rafts in H/N-Ras/ MEFs restores PLA2 activation.
3H-labeled arachidonic acid release
was measured in H/N-Ras/ MEFs transfected with wild-type H-Ras targeted to its different microlocalizations (1 g) after stimulation with EGF.
Shown are the averages  standard errors of the means of the results from two experiments relative to the levels detected in unstimulated cells
transfected with the respective site-specific, wild-type H-Ras constructs. *, P  0.05, with a 95% confidence interval. (F) The restoration of Ras
at lipid rafts in H/N-Ras/ MEFs does not affect RSK1 activation. Total and phosphorylated RSK1 levels were determined for H/N-Ras/ MEFs
transfected with LCK- or CD8-tethered wild-type H-Ras (1 g) after stimulation with EGF (). Targeted H-Ras protein expression levels were
determined by anti-HA immunoblotting. , anti; c, control.
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those cells harboring disordered membrane- or Golgi-tethered
Ras. Conversely, the restoration of H-Ras at lipid rafts had no
effects in the phosphorylation of RSK1 induced by EGF, which
was slightly augmented in those cells transfected with disor-
dered membrane-tethered Ras (Fig. 3F). These results dem-
onstrated that, both in physiological contexts and in ectopic
expression systems, the Ras signaling platform regulated
ERK1/2 selectivity toward different substrates.
Sublocalization dictates ERK1/2 substrate selectivity under
physiological stimulation. Subsequently, we asked whether for
external stimuli acting upstream of Ras, ERK1/2 also exhibited
a localization-dependent substrate selectivity. To this end, we
engineered AU5-tagged ERK2 constructs specifically tethered
to disordered membrane and to lipid rafts (Fig. 4A), from
which the activations of RSK1 and EGFr were, respectively,
regulated. Such constructs would enable us to monitor ERK2
activation in the immediate proximity of these microenviron-
ments, upon the receipt of external stimuli. To verify the re-
sponse specificity of these constructs to signals emanating from
lipid rafts or disordered membrane, they were cotransfected
with CD8- and LCK-RasV12. As shown in Fig. 4B, CD8-
RasV12 only induced the phosphorylation of the disordered
membrane-tethered ERK2, whereas LCK-RasV12 just af-
fected lipid raft-bound ERK2, thereby corroborating their spa-
tial specificity.
These constructs were transfected in 293T cells that were
then treated with different agonists. Interestingly, the activa-
tion of ERK2 at these microdomains followed different kinet-
ics depending on the stimulus. At lipid rafts, upon treatment
with EGF, the phosphorylation of ERK2 reached a rapid max-
imum after just 2 min and faded progressively afterwards.
Conversely, at the disordered membrane, ERK2 exhibited a
FIG. 4. Sublocalization dictates ERK1/2 substrate selectivity under physiological stimulation. (A) Subcellular fractionation of targeted ERK2
proteins. 293T cells expressing AU5-tagged ERK2 specifically tethered to lipid rafts (LCK) or to the disordered membrane (CD8) (1 g) were
solubilized in 0.25% Triton X-100 and partitioned in a sucrose gradient. The presence of the targeted ERK2 proteins in the different fractions was
analyzed by anti-AU5 immunoblotting. Anti-caveolin-1 ( Cav) identifies the lipid raft fractions, and anti-transferrin receptor ( Tfr) identifies the
disordered membrane fractions. (B) Targeted ERK2 proteins recognize signals in site-specific fashion. Cells were transfected with LCK- or
CD8-AU5-tagged ERK2 in addition to LCK-RasV12 or CD8-RasV12 (1 g each) as shown. Total and phosphorylated ERK levels were examined
in anti-AU5 immunoprecipitates. (C) Time-dependent activation profiles of the targeted ERK2 proteins. 293T cells were transfected with the
tethered ERK2 constructs and their kinetics of activation were compared when stimulated with EGF (10 ng/ml), LPA (5 M), or TPA (100 nM)
for the indicated times (in minutes) by monitoring total and phosphorylated ERK levels in anti-AU5 immunoprecipitates. For comparison, the
phosphorylation kinetics of endogenous ERK1/2 are shown (top two panels). (D) EGFr phosphorylation correlates with the activation of ERK2
at lipid rafts. 32P-labeled 293T cells were stimulated, after starvation, with LPA for the indicated times and phosphorylation of the EGFr was
analyzed. Notice that the kinetics of EGFr phosphorylation match those of LCK-ERK2 stimulated with LPA. (E) RSK1 phosphorylation correlates
with the activation of ERK2 at the disordered membrane and varies accordingly depending on the stimulus. 293T cells were stimulated, after
starvation, with EGF or TPA for the indicated times, and the phosphorylation of RSK1 was analyzed. Notice that the kinetics of RSK1 activation
match those of CD8-ERK2 stimulated with EGF or with TPA.
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slower phosphorylation course, with a late peak 10 min after
stimulation that was still apparent after 30 min (Fig. 4C).
Stimulation with LPA evoked a similar pattern of activation:
the activation of ERK2 at the disordered membrane lagged
behind that one taking place at lipid rafts. Interestingly, when
cells were treated with the phorbol ester TPA, ERK2 followed
similar patterns of activation at both localizations, with robust
peaks 5 min after stimulation that were sustained after 30 min.
We then examined if the kinetics of ERK2 activation at lipid
rafts and disordered membrane correlated with the activation
patterns exhibited by those substrates specifically regulated
from each of these localizations, namely, EGFr and RSK1. In
a physiological setting, such as parental 293T cells stimulated
with LPA, the phosphorylation of EGFr displayed a maximum
after 5 min, decreasing thereafter (Fig. 4D). Noticeably, this
activation course was similar to the one exhibited by ERK2 at
lipid rafts upon LPA stimulation (Fig. 4C). In the same fash-
ion, the phosphorylation of RSK1 induced by EGF displayed a
late onset (Fig. 4D). Remarkably, RSK1 activation paralleled
EGF-induced ERK2 activation at the disordered membrane.
More interestingly, the RSK1 activation pattern completely
changed when the activating stimulus was TPA (Fig. 4D). In
this case, its kinetics resembled that of TPA-induced ERK2
activation at disordered membrane, with an early peak and
sustained activation. These results added further support to
the notion that, regardless of the activating stimulus, the mi-
croenvironment in which ERK1/2 are activated dictates their
substrate selectivity.
cPLA2 and RSK1 occupy distinct subcytoplasmic domains.
We wished to understand how two substrates that, supposedly,
shared the same subcellular compartment were distinctively
selected by ERK1/2 activated at different localizations. We
hypothesized that even though RSK1 and cPLA2 both reside at
the cytoplasm, they could be present at different microdo-
mains. To test this possibility, we explored the localizations of
RSK1 and cPLA2 by immunofluorescence. Interestingly, even
though these two proteins exhibited clear cytoplasmic staining,
hardly any colocalization was apparent, suggesting that they
could be occupying different sites within the cytoplasm (Fig.
5A, profile A). Next, we examined the colocalization of these
two substrates with activated ERK1/2 in cells in which the
activating Ras signal originated at different sites. In cells ex-
pressing RasV12 at lipid rafts, phosphorylated ERK1/2 mark-
edly colocalized at the cytoplasm with cPLA2, in particular in
the perinuclear region and at the cellular periphery (Fig. 5B,
profile B), but very little colocalization with RSK1 was evident
(Fig. 5C). Conversely, in cells expressing RasV12 at the disor-
dered membrane, a profuse colocalization of phosphorylated
ERK1/2 with RSK1 but not with cPLA2 was apparent (Fig. 5D
and E). We studied the microlocalization of these substrates in
further detail by immunogold electron microscopy, in which
cPLA2 and RSK1 were labeled with gold particles of different
diameters. Interestingly, instead of appearing intermixed and
randomly scattered throughout the cytoplasm, both cPLA2 and
RSK1 formed clusters at specific sites, clearly separated from
each other (Fig. 6 and Table 1). This was not a general feature
for all cytoplasm residents, since both cPLA2 and RSK1 were
intermixed with another cytoplasmic protein such as ubiquitin
(data not shown). These results suggested that depending on
the membrane localization from which the Ras signal ema-
nated, activated ERK1/2 were directed to defined subcytoplas-
mic compartments where different substrates resided.
ERK1/2 site-specific substrate selectivity entails distinct us-
age of scaffold proteins. It was important to understand the
molecular mechanisms underlying ERK1/2 site-dependent
substrate specificity. Since some scaffold proteins have been
shown to regulate ERK1/2 signals in a localization-regulated
fashion (17), we investigated their implication in substrate
specificity. To this end, we first analyzed the activation of
several ERK substrates when the expression of KSR1, a scaf-
fold involved in ERK1/2 signaling orchestrated from lipid rafts
(22), was downregulated by siRNA interference in 293T cells.
Whereas the reduction of KSR1 levels forestalled EGF-in-
duced cPLA2 activation by more than 75%, RSK1 phosphory-
lation was completely unaltered (Fig. 7A). Furthermore, grad-
ually increasing the amount of KSR1 that was transfected
resulted in a biphasic cPLA2 activation pattern in response to
EGF stimulation, typical of scaffold proteins, whereas RSK1
activation was, again, unaffected (Fig. 7B). These results sug-
FIG. 5. RSK and cPLA2 are located in distinct subcytoplasmic microlocalizations. (A) RSK and cPLA2 do not colocalize. Growing NIH 3T3 cells
were costained with anti-RSK and anti-cPLA2 antibodies and visualized by immunofluorescence and confocal microscopy. (B and C) cPLA2 but not
RSK1 colocalizes with phospho-ERK (p-ERK) in NIH 3T3 cells stably expressing LCK-RasV12. Inset, detail of the sublocalization at the cytoplasm
(thick arrow). (D and E) RSK1 but not cPLA2 colocalizes with phospho-ERK in NIH 3T3 cells stably expressing CD8-RasV12. To highlight the
cytoplasmic signals, the cells were not permeabilized (except in panel B), and the nuclear signals are quenched. Pseudocolors were red and green and
as indicated; yellow indicates a merge. Scale bar 	 10 M. Profile A, pseudocolor intensity profile, across the section shown in panel A. Notice that the
colocalization of peaks is minimal. Profile B, pseudocolor intensity profile at a PM localization (thin arrow) shown in panel B.
FIG. 6. RSK1 and cPLA2 occupy distinct cytoplasmic microdo-
mains. Immunogold electron microscopy was performed on NIH 3T3
cells. The secondary antibodies disclosing RSK1 (asterisks) and cPLA2
(arrows) were labeled with 15-nm and 10-nm gold particles, respec-
tively. Scale bar 	 100 nm.
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gested that KSR1 was the scaffold utilized by ERK1/2 for
activating cPLA2 but not RSK1.
Following this argument, we examined whether KSR1 cou-
pled ERK and cPLA2 activations in a site-dependent fashion.
To do so, we analyzed the composition of the KSR1 complex
upon the receipt of Ras signals originated at different localiza-
tions. It was found that the levels of total and phosphorylated
ERK1/2 that assembled to endogenous KSR1 markedly in-
creased in cells stimulated with EGF and in those transfected
with lipid raft-associated RasV12 but not in those expressing
RasV12 tethered to the disordered membrane (Fig. 7C). These
results were ascertained in the entirely physiological back-
ground offered by the H/N-Ras null MEFs and under ectopic
stimulation. Whereas in wild-type MEFs EGF induced an in-
crease in the total and phosphorylated ERK1/2 bound to en-
dogenous KSR1, in H/N-Ras/ MEFs, devoid of Ras at lipid
rafts, the levels of total and activated ERK1/2 which associated
with KSR1 upon EGF stimulation where unchanged (Fig. 7D).
Most interestingly, endogenous cPLA2 was completely absent
from KSR1 immunoprecipitates under resting conditions, but
significant proportions of cPLA2 were found to associate with
KSR1 in cells stimulated with EGF or transfected with lipid
raft-associated RasV12. As we had previously demonstrated
(8), the interaction between cPLA2 and KSR1 was completely
dependent on ERK1/2 activation, since preincubation with
UO126 completely inhibited cPLA2 binding to KSR1 (Fig.
7E). On the other hand, RSK1 was found not to associate with
KSR1, either in cells transfected with H-RasV12 or in response
to EGF stimulation (Fig. 7E). In a similar fashion, in wild-type
MEFs, EGF induced a marked incorporation of cPLA2 to the
KSR1 complex, whereas in H/N-Ras/ MEFs, the levels of
cPLA2 which associated with KSR1 upon EGF stimulation
where minimal (Fig. 7F).
These results were further substantiated by immunofluores-
cence studies, in which, in wild-type MEFs, cPLA2 was shown
to profusely colocalize with KSR1 at PM localizations in re-
sponse to EGF stimulation (Fig. 8A and B, arrows), while such
interaction was lost in H/N-Ras/ MEFs (Fig. 8C and D). An
identical situation was observed in biochemical studies evalu-
ating EGF-induced KSR1 and cPLA2 association with the PM,
extracted from these two types of MEFs (Fig. 9). Overall, these
results supported the notion that KSR1 coupled activated
ERK1/2 selectively to its substrate, cPLA2, in response to sig-
nals generated at lipid rafts.
In light of our data demonstrating that cPLA2 could be
activated from distinct Ras platforms, though to different ex-
tents, we then investigated whether KSR1 would couple
ERK1/2 to the activation of cPLA2, irrespective of the site
where the activating Ras signal was generated. For this, we
evaluated cPLA2 activation in 293T cells transfected with
RasV12, tethered to lipid rafts, the ER, and the disordered
membrane, plus a siRNA against KSR1. It was found that the
downregulation of KSR1 expression affected only cPLA2 acti-
vation elicited from lipid rafts and not that resulting from Ras
activation at the ER or at the disordered membrane (Fig.
10A), thereby demonstrating that KSR1 exhibited both sub-
strate and localization specificity.
It was of interest to identify the scaffold protein that coupled
ERK to cPLA2 activation when the Ras signal was coming
from the ER. To do so, we analyzed the activation of cPLA2
under conditions where the availability of different scaffold
proteins was reduced. The 293T cells were transfected with
ER-targeted RasV12 and siRNAs against a set of well-known
ERK1/2 scaffolds, namely, dystroglycan, IQGAP1, KSR1, -ar-
restin, MORG, MP-1, paxillin, and Sef. These siRNAs effi-
ciently downregulated the expression of all the scaffold pro-
teins tested (8), but only the drop in Sef expression levels had
a negative impact on cPLA2 activation induced by ER Ras
(Fig. 10B). Moreover, increasing concentrations of ectopically
expressed Sef brought about a biphasic response for cPLA2
activation (Fig. 10C), pointing to Sef having a scaffold function
in this process. We next asked if Sef would also intervene in
cPLA2 activation as regulated from other sublocalizations. In
this respect, cPLA2 activation induced by lipid raft-targeted
RasV12 was completely unaffected by the siRNA-induced drop
in Sef expression (Fig. 10D). Furthermore, when we analyzed
the composition of Sef complexes upon the receipt of Ras
signals originated at different localizations, cPLA2 associated
with Sef in an activated ERK-dependent fashion in cells trans-
fected with ER-bound RasV12 but not in those expressing lipid
raft-associated RasV12 (Fig. 10E). In conclusion, these results
indicated that Sef was the scaffold protein specifically regulat-
ing cPLA2 activation by ERK1/2 responding to Ras signals
coming from the ER.
Our results had demonstrated that Ras signals from lipid
rafts regulated the phosphorylation of two ERK substrates,
cPLA2 and EGFr, and that KSR1 was the ERK scaffold me-
diating in cPLA2 activation. As such, we questioned whether
KSR1 also participated in ERK1/2 signals directed to EGFr,
thus behaving as a “general” lipid raft scaffold. Remarkably,
EGFr phosphorylation resulting from Ras activation at lipid
rafts was unaffected by the downregulation of KSR1 levels
(Fig. 11A), speaking against KSR1 having a scaffold role in the
activation of this substrate. Accordingly, we looked for the
scaffold mediating in this event by assaying the phosphoryla-
tion of EGFr, as induced by lipid raft-tethered RasV12, under
limiting levels of scaffold proteins, brought about by the utili-
zation of the siRNA battery mentioned before. In this case, it
was found that a drop in IQGAP1 expression evoked a marked
reduction in EGFr phosphorylation (Fig. 11B). Further, in
cells transfected with lipid raft-tethered RasV12, IQGAP1 was
found in association with the EGFr (Fig. 11C), thereby point-
ing to IQGAP1 as the scaffold participating in the lipid raft-
induced ERK signal, directed to this particular substrate. Since
Ras signals derived from lipid rafts also regulated the activation of
cPLA2, we tested whether IQGAP1 could also intervene in this
TABLE 1. RSK and cPLA2 are located in distinct
subcytoplasmic microlocalizationsa
Particles Distance between goldparticles (nm) P value
cPLA2-cPLA2 8.21  1.21 
0.5
RSK1-RSK1 8.02 1.88 
0.5
cPLA2-RSK1 160.82  13.08 0.005
a Distance between RSK1 and cPLA2 particles. Immunogold electron micros-
copy was performed with NIH 3T3 cells. The secondary antibodies disclosing
RSK1 and cPLA2 were labeled with 15-nm and 10-nm gold particles, respec-
tively. Results show the distances between gold particles as the averages 
standard errors of the means of six sections. Student’s t test highlights the
significance of the distance between RSK1 and cPLA2.
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process. It was found that the siRNA-mediated depletion of IQ-
GAP1 levels did not affect whatsoever cPLA2 activation as in-
duced by RasV12 acting at lipid rafts (Fig. 11D).
Subsequently, we set out to find the scaffold protein medi-
ating the phosphorylation of RSK1, as induced by Ras signals
flowing from the disordered membrane. With this aim, once
again, we utilized the set of siRNAs previously described in
cells expressing RasV12 tethered to this specific sublocaliza-
tion. Interestingly, the levels of RSK1 phosphorylation re-
mained unaltered in all cases (Fig. 11E), suggesting that none
of the tested scaffold proteins participated in the disordered
membrane-evoked ERK signal targeting RSK1. Overall, these
results supported the notion that Ras localization within dif-
ferent membrane microdomains could dictate ERK1/2 sub-
strate specificity and that such an effect was possible due to the
selective participation of defined scaffold proteins.
FIG. 7. KSR1 couples Ras signals from lipid rafts to cPLA2 activation. (A) Depletion of KSR1 prevents cPLA2 but not RSK1 activation. 293T cells
were transfected with () or without (-) a siRNA (10 nM) for KSR1 and stimulated with EGF (10 ng/ml, 5 min) after starvation. Endogenous cPLA2
activation was determined by [3H]arachidonic acid release. Bottom panels show total and phosphorylated RSK1 (p-RSK1), and KSR1 levels were
determined by immunoblotting. (B) Biphasic activation of cPLA2 resulting from increasing KSR1 levels. Cells were transfected with increasing
concentrations of FLAG-KSR1 and stimulated with EGF after starvation. Bottom panels show total and phosphorylated RSK1, and KSR1 (FLAG) levels
were determined by immunoblotting. (A and B) Shown are the averages  standard errors of the means of the results from three independent
experiments relative to the levels in starved (C) cells. (C) ERK1/2-KSR1 association is enhanced by Ras signals from lipid rafts but not the disordered
membrane. Endogenous ERK1/2, total and phosphorylated, present in native KSR1 immunoprecipitates was determined in cells transfected with RasV12
(0.5 g) tethered to lipid rafts (LCK) or to the disordered membrane (CD8) or stimulated with EGF. (D) ERK1/2-KSR1 association is enhanced in
wild-type but not in H/N-Ras/ MEFs. ERK1/2, total and phosphorylated, present in KSR1 immunoprecipitates were analyzed in MEFs, starved (C) or
EGF stimulated. (E) The association of KSR1 and endogenous cPLA2 is enhanced by EGF stimulation and by Ras signals from lipid rafts and is inhibited
by UO126 (2 M, 25 min prior to stimulation). Bottom panels, RSK1 does not associate with KSR1 in response to Ras signals coming from lipid rafts
or to EGF stimulation. (F) The association of KSR1 and endogenous cPLA2 in response to EGF is diminished in H/N-Ras
/ MEFs compared to
wild-type fibroblasts. TL, total lysate; IP, immunoprecipitations performed with a specific antibody; PI, immunoprecipitations performed with preimmune
serum; , anti.
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Finally, we examined the extent to which scaffold usage
could influence the biological output of Ras site-specific sig-
nals. It has been shown that KSR1 is an essential mediator in
Ras-induced replicative senescence (18). As such, we tested
how site-specific Ras signals coupled to KSR1, such as those
emanating from lipid rafts, could induce replicative senescence
compared to those generated at the disordered membrane,
which we have shown not to utilize KSR1. To this end, wild-
type MEFs (/) were transfected with the constructs ex-
pressing RasV12 at lipid rafts and the disordered membrane.
In these cells, both site-specific signals were capable of pro-
moting transformation, slightly more prominently in the case
of those signals generated at the disordered membrane (Fig.
12A). However, the situation was completely reversed when we
monitored their ability to induce senescence: whereas the
amount of -galactosidase-positive / MEFs resulting from
the expression of lipid raft-tethered RasV12 was similar to that
encountered in cells transfected with “total” RasV12, their
numbers were reduced by more than 50% in MEFs transfected
with RasV12 bound to the disordered membrane (Fig. 12B).
To test the participation of KSR1 in this process, we repeated
the same experiment with MEFs devoid of KSR1 (/) (18).
It was found that the absence of this scaffold dramatically
reduced the ability of the different Ras constructs to induce
senescence in all cases, though less pronouncedly in the case of
disordered membrane-targeted CD8-RasV12. Likewise, when
the levels of KSR1 were reconstituted by ectopic expression,
the regained capacity of the Ras signals emanating from the
disordered membrane to induce senescence was far lower than
the one exhibited by Ras signals coming from lipid rafts (Fig.
FIG. 8. KSR1 and cPLA2 colocalize at the PM of wild-type (wt) but not H/N-Ras
/ (/) MEFs. Endogenous RSK and cPLA2 were
costained with anti-RSK and anti-cPLA2 antibodies and visualized by immunofluorescence and confocal microscopy. The wild-type and H/N-
Ras/ MEFs were starved (A and C) or stimulated with EGF (10 ng/ml, 5 min) (B and D). Pseudocolors were red and green as indicated; yellow
indicates a merge. Scale bar 	 10 M.
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12B). In agreement with our biochemical data, these results
demonstrated that the biological responses caused by Ras sig-
naling from the disordered membrane were mostly indepen-
dent of KSR1, whereas those resulting from Ras signals orig-
inating at lipid rafts were strongly dependent on the presence
of this scaffold protein.
DISCUSSION
An essential requirement for an efficient signal transduction
system is a fast response upon the receipt of a stimulus. This
can be accomplished by triggering immediate associations and
functional interactions among its constituents. However, con-
sidering that the environment in which most of these reactions
take place, the cytoplasm, is densely crowded and mostly oc-
cupied by organelles and macromolecular complexes, it seems
unlikely that such instantaneous reactions could be achieved if
the signaling intermediaries were randomly scattered. To over-
come this problem, one possibility would be that signaling
molecules resided in defined subcytoplasmic confinements, in a
preassembled mode, so as to guarantee a swift wiring, connect-
ing those sites at which the signal is received to the desired
effectors at particular cellular locations. The results presented
herein support this notion.
We show that the Ras signaling platform from which the
activating signals originate dictates ERK1/2 substrate specific-
ity. Our results indicate that the phosphorylation of PM sub-
strates, like EGFr, is preferentially regulated from lipid rafts.
This is consistent with the EGFr being highly concentrated in
this type of membrane (39). Regarding ERK1/2 cytoplasmic
substrates, our results point to variations in the spatial regula-
tion of their activation. As such, cPLA2 is primarily regulated
by lipid raft-generated Ras signals, once again consistent with
the physical and functional association of cPLA2 with lipid
rafts, caveolar in particular (2, 25). On the other hand, the
activation of RSK1 is regulated from the disordered mem-
brane. An explanation for this divergent regulation for two
substrates that a priori reside within the same compartment is
that, within the cytoplasm, they occupy distinct microlocaliza-
tions. In support of this notion, our electron microscopy data
demonstrate that these two cytoplasmic proteins are clustered
in clearly separated cytoplasmic microdomains. Thus, it can be
envisioned that upon the activation of Ras at lipid rafts or at
the disordered membrane, activated ERK1/2 would be, respec-
tively, directed to cPLA2- or to RSK1-enriched cytoplasmic
confinements. Indeed, we demonstrate that Ras activity at lipid
rafts induces the colocalization of phosphorylated ERK1/2
with cPLA2 but not with RSK1, whereas RSK1 but not cPLA2
colocalizes with activated ERK1/2 when the activating Ras
signals emanate from the disordered membrane.
Importantly, we demonstrate that the coupling of ERK1/2 to
specific substrates depending on the activating signaling plat-
form is not solely restricted to oncogenic Ras-generated signals
but also applies to physiological agonists, like EGF and LPA,
and to drugs like TPA. Indeed, in an entirely physiological
context, we show that ERK activation kinetics at defined lo-
calizations resembles those of its cognate substrates and that
both fluctuate in parallel depending on the stimulus. As such,
EGFr activation kinetics are similar to those for ERK2 at lipid
rafts, whereas the time course of RSK1 activity mirrors that of
ERK2 at the disordered membrane.
With respect to ERK1/2 nuclear substrates, we have exam-
ined the activation of the transcription factor Elk1. We have
found that its activation is not due solely to ERK1/2 activity but
also to JNK1/2, but not to p38. Interestingly, the JNK compo-
nent displays a clear spatial regulation, being the Ras signals
emanating from endomembranes, in particular from the Golgi
complex, the most sensible to JNK1/2 depletion. This result is
in agreement with our previous findings, in which Ras at these
localizations exhibited the most prominent JNK activation
(21). Regarding the ERK1/2 component, unlike membrane
and cytoplasmic substrates, our results indicate that the acti-
vation of nuclear substrates is mostly independent of the Ras
sublocalization from which ERK1/2 are switched on. Interest-
ingly, we show that untargeted RasV12 elicits a much stronger
Elk1 activation than the site-specific RasV12 constructs. It
must be noticed that our site-specific Ras proteins are fixed to
their compartments, whereas untargeted Ras is free to trans-
locate between localizations and the cytoplasm (31). This could
cause differences in signal intensities and therefore impact the
resulting biological outcomes. Also, another possibility is that
a more-efficient Elk1 transactivation takes place under the
input from several Ras sublocalizations, attainable by unteth-
ered Ras molecules free to move, while, as elicited by the
site-specific, single signals generated by our targeted Ras pro-
teins, Elk1 activation may be less effective.
Herein we demonstrate that ERK1/2 selectivity toward dif-
ferent substrates, dependent on Ras sublocalization, is attained
through the participation of specific scaffold proteins, which
mediate such an interaction. We show that ERK1/2 activated
by signals originating at lipid rafts are coupled to cPLA2 by the
participation of KSR1. Interestingly, KSR1 is not the only
scaffold utilized in ERK1/2-mediated signaling routes emanat-
ing from lipid rafts, as we demonstrate that the ERK-induced
phosphorylation of EGFr is regulated not by KSR1 but by
IQGAP1. Another concept unveiled by our present results is
that targeting a defined substrate is not exclusive for a given
FIG. 9. KSR1 and cPLA2 localize at the PM of wild-type (wt) but
not H/N-Ras/ MEFs upon stimulation. Soluble (S100) and particu-
late (P100) fractions were isolated from wild-type and H/N-Ras/
MEFs, starved () or stimulated () with EGF (10 ng/ml, 5 min). The
presence of KSR1 and cPLA2 was examined by immunoblotting. The
purity of the fractions was ascertained by blotting against Rho-GDP
dissociation inhibitor (GDI) and transferrin (Tfr) receptor in lysates
from wild-type MEFs.
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scaffold protein. In this respect, we demonstrate that cPLA2
activation is regulated by KSR1 when ERK1/2 are activated
from lipid rafts, whereas Sef is the mediator if the ERK1/2-
activating signal evolves from the ER. While the association of
IQGAP1 with EGFr has been previously reported (7), the
interactions of cPLA2 with KSR1 or with Sef were unknown
before our studies (8). Noticeably, we have observed that the
activation of the cytoplasmic kinase RSK1 by signals coming
from the disordered membrane is unaffected by the depriva-
tion of the best-known scaffold proteins. Even though we can-
not ultimately discard the idea that such a reaction takes place
in an unscaffolded fashion, our previous results indicating that
the depletion of ERK dimers affects RSK1 phosphorylation (8)
suggest the participation of some scaffold. It is possible that the
limited tactic that we have utilized herein has not allowed us to
identify the scaffold mediating in this pathway and that an
unbiased, genome-wide approach is necessary.
Having acquired the notion of scaffold proteins playing an
FIG. 10. Sef couples Ras signals from the ER to cPLA2 activation. (A) Depletion of KSR1 inhibits cPLA2 activation by Ras signals from lipid
rafts but not from the ER or disordered membrane. 293T cells were transfected with RasV12 (0.5 g) tethered to lipid rafts, the ER, and the
disordered membrane with () or without () a siRNA (10 nM) for KSR1. (B) Effects of depleting the levels of different scaffold proteins on
cPLA2 activation by Ras signals from the ER. Cells were transfected with ER-targeted RasV12 (M1) () plus siRNAs (10 nM) for the shown
scaffold proteins. DGLY., dystroglycan;  ARR. 2, -arrestin 2; PAXILL., paxillin. (C) cPLA2 activation by Ras signals from the ER exhibits a
biphasic response to increasing Sef concentrations. Cells were transfected with ER-targeted RasV12 (M1) (), in addition to increasing
concentrations of Myc-Sef as shown. (D) Sef does not intervene in cPLA2 activation elicited from lipid rafts. Cells were transfected with RasV12
tethered to lipid rafts with () or without (-) a siRNA against Sef. (A to D) cPLA2 activation was determined by [
3H]arachidonic acid release after
18 h of starvation. Shown are the averages  standard errors of the means of the results from three independent experiments relative to the levels
in starved (C) cells. (E) Sef/cPLA2 association is enhanced by Ras signals from the ER but not from lipid rafts. Endogenous cPLA2, present in
anti-Myc ( Myc) immunoprecipitates, was determined in cells transfected with Myc-Sef (1 g) plus RasV12 tethered to lipid rafts (LCK) or to
the ER (M1). The dependence on ERK was determined by incubation with UO126 (2 M, 25 min prior to stimulation). TL, total lysate; IP,
immunoprecipitations performed with a specific antibody; PI, immunoprecipitations performed with preimmune serum.
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essential role in the spatial regulation of Ras sublocalization-
directed ERK1/2 substrate specificity, our data showing that
the activation of ERK1/2 nuclear substrates is not dependent
on the Ras signaling platform are further endorsed by previous
reports demonstrating that scaffold proteins such as KSR1
(34), -arrestin (11, 36), and Sef (37) are mostly involved in
cytoplasmic events and that their effects on ERK-mediated
nuclear effects are limited. In line with these findings, our
recent results demonstrate that scaffolds act as dimerizing plat-
forms for ERK1/2 and, subsequently, serve in the activation
of cytoplasmic substrates, undertaken by ERK1/2 dimers,
whereas they are dispensable for the activation of nuclear
substrates exerted by ERK1/2 monomers (8).
As of today, the mechanisms whereby ERK1/2 scaffold com-
plexes respond to localization-defined Ras signals and how
they can be directed to different subcytoplasmic microenviron-
ments, to target different substrates, are completely unknown
and under investigation. One possibility is the existence of
FIG. 11. IQGAP1 couples Ras signals from lipid rafts to EGFr phosphorylation. (A) Depletion of KSR1 does not affect the phosphorylation
of EGFr elicited by Ras signals from lipid rafts. 293T cells were transfected with lipid raft-targeted RasV12 (LCK) (0.5 g) plus a siRNA (10 nM)
() for KSR1. EGFr phosphorylation was determined by immunoprecipitation (IP) in 32P-labeled cells. (B) Effects of downregulating the levels
of different scaffold proteins on EGFr phosphorylation induced by Ras signals from lipid rafts. Cells were transfected with lipid raft-targeted
RasV12, plus siRNAs for the shown scaffold proteins. DGLY., dystroglycan;  ARR. 2, -arrestin 2; PAXILL., paxillin. (C) EGFr/IQGAP1
association is enhanced by Ras signals from lipid rafts. Endogenous IQGAP1, present in anti-EGFr immunoprecipitates, was measured in cells
transfected with RasV12, untargeted or tethered to lipid rafts (LCK). TL, total lysate; IP, immunoprecipitations performed with a specific antibody;
PI, immunoprecipitations performed with preimmune serum. (D) IQGAP1 does not intervene in cPLA2 activation elicited from lipid rafts. Cells
were transfected with RasV12 tethered to lipid rafts with () or without () a siRNA against IQGAP1. cPLA2 activation was determined by
[3H]arachidonic acid release after starvation. (E) RSK1 phosphorylation by Ras signals from the disordered membrane is unaffected by the
depletion of scaffold proteins. Cells were transfected with disordered membrane-targeted RasV12 (CD8), plus siRNAs (10 ng) for the shown
scaffold proteins. Total and phosphorylated RSK1 levels were detected by immunoblotting. , anti.
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microlocalization-specific determinants within the structure of
scaffold proteins, which could orchestrate ERK1/2 signals in a
spatially dependent fashion. This possibility is supported by the
fact that some scaffold proteins regulate ERK1/2 signals spe-
cifically at localizations like the Golgi complex (37), endo-
somes (35), and focal adhesions (16). Overall, our results dis-
close a novel mechanism whereby space can regulate the
outcome of a signal by a selective wiring connecting the sites at
which such a signal emanates for the activation of defined
substrates through the specific intervention of molecular inter-
mediaries, which are, in this particular case, scaffold proteins.
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